Efficacy News and Research

RSS
Merck announces results from ISENTRESS Phase III combination study on HIV-1

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Micromet receives FDA feedback on blinatumomab registration for R/R ALL

Micromet receives FDA feedback on blinatumomab registration for R/R ALL

BCL11A protein might serve as potential target for sickle cell disease

BCL11A protein might serve as potential target for sickle cell disease

Cylene advances preclinical development of CX-5461 for treatment of cancer

Cylene advances preclinical development of CX-5461 for treatment of cancer

Hydromorphone can be as effective as diacetylmorphine in treating heroin addiction

Hydromorphone can be as effective as diacetylmorphine in treating heroin addiction

Autism Speaks announces 10 new research grants

Autism Speaks announces 10 new research grants

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

Intellikine commences INK1117 Phase I dose escalation study in cancer

Intellikine commences INK1117 Phase I dose escalation study in cancer

AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01

AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01

NIH awards United Therapeutics $45 million contract to develop potential oral treatment for viruses

NIH awards United Therapeutics $45 million contract to develop potential oral treatment for viruses

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes

Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes

Patients with poorly controlled diabetes may benefit from behavioral, educational interventions

Patients with poorly controlled diabetes may benefit from behavioral, educational interventions

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

Gantenerumab appears to reduce brain amyloid levels in patients with AD

Gantenerumab appears to reduce brain amyloid levels in patients with AD

Coridon demonstrates 100% protection using DNA HSV-2 vaccine

Coridon demonstrates 100% protection using DNA HSV-2 vaccine

Targacept commences AZD3480 Phase 2b study in Alzheimer’s disease

Targacept commences AZD3480 Phase 2b study in Alzheimer’s disease

AIT Laboratories introduces new suite of services for prescription compliance monitoring

AIT Laboratories introduces new suite of services for prescription compliance monitoring

Unither Virology receives NIAID contract for glycobiology antiviral platform

Unither Virology receives NIAID contract for glycobiology antiviral platform

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.